切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2024, Vol. 17 ›› Issue (04) : 659 -662. doi: 10.3877/cma.j.issn.1674-6902.2024.04.033

综述

维生素D对肺部疾病临床意义的研究进展
白若靖1, 郭军1,()   
  1. 1. 102218 北京,清华大学附属北京清华长庚医院 清华大学临床医学院老年医学科
  • 收稿日期:2024-02-23 出版日期:2024-08-25
  • 通信作者: 郭军
  • 基金资助:
    清华大学精准医学科研计划(QT201901); 北京市卫生健康委员会高层次公共卫生技术人才建设项目培养计划(学科带头人-02-06)

Advancements in the study of the clinical significance of vitamin D in pulmonary diseases

Ruojing Bai, Jun Guo()   

  • Received:2024-02-23 Published:2024-08-25
  • Corresponding author: Jun Guo
引用本文:

白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.

Ruojing Bai, Jun Guo. Advancements in the study of the clinical significance of vitamin D in pulmonary diseases[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 659-662.

维生素D(vitamin D)是一种脂溶性的开环固醇类物质[1]。维生素D2(多骨化醇)和维生素D3(胆钙化醇或骨化二醇[25-羟维生素D3,25(OH)D],骨化三醇[1,25-二羟维生素D3,1,25(OH)2D])是维生素D的两种主要形式[2]。维生素D2主要来自植物和真菌,维生素D3主要存在于动物中,或是皮肤经过紫外线照射下自然合成。维生素D的功能包括调节人体钙、磷的稳态和控制骨代谢。维生素D缺乏会影响骨骼健康,还会导致多种慢性疾病,这些疾病通常伴随着炎症增加和免疫系统失调,如糖尿病、哮喘和类风湿性关节炎[3]。维生素D的生物活性形式是1,25-二羟基维生素D[1,25(OH)2D],也被称为"D激素"或"活性维生素D"[1],通过与维生素D受体(vitamin D receptor, VDR)结合并直接调节维生素D靶组织(如肠道、肾脏和骨骼)中的基因表达来发挥作用[4]。根据《维生素D及其类似物临床应用共识》,维生素D摄入不足者的的治疗剂量为:0~1岁400~1 000 IU/d;2~18岁600~1 000 IU/d;19~50岁1 500~2 000 IU/d;50岁以上1 600~2 000 IU/d[1]

1
中华医学会骨质疏松和骨矿盐疾病分会. 维生素D及其类似物的临床应用共识[J]. 中华内分泌代谢杂志2018, 34(3): 187-200.
2
Gibbons JB, Norton EC, McCullough JS, et al. Association between vitamin D supplementation and COVID-19 infection and mortality[J]. Sci Rep, 2022, 12(1): 19397.
3
Sassi F, Tamone C, D′Amelio P. Vitamin D: nutrient, hormone, and immunomodulator[J]. Nutrients, 2018, 10(11): E1656.
4
Verlinden L, Carmeliet G. Integrated view on the role of vitamin D actions on bone and growth plate homeostasis[J]. JBMR Plus, 2021, 5(12): e10577.
5
Nuwagira E, Stadelman A, Baluku JB, et al. Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study[J]. Trop Med Health, 2020, 48(1): 34.
6
Gayan-Ramirez G, Janssens W. Vitamin D actions: the lung is a major target for vitamin D, FGF23, and klotho[J]. JBMR Plus, 2021, 5(12): e10569.
7
Zhu M, Wang T, Wang C, et al. The association between vitamin D and COPD risk, severity, and exacerbation: An updated systematic review and meta-analysis[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2597-2607.
8
潘晓芳,吴静标,黄燕虹,等. 我国25-羟基维生素D检测方法及其研究进展[J]. 分子诊断与治疗杂志2020, 12(12): 1591-1595.
9
张诗颜,卓 影,王庭强,等. 维生素D和肠道菌群对结直肠癌的预防作用[J]. 中国卫生标准管理2023, 14(10): 189-193.
10
周晓春,陈 晓. 维生素D与2型糖尿病关系的研究进展[J]. 中国全科医学2014, 17(14): 1577-1580.
11
邓杰忠,杨宇生,何晋月,等. 1,25(OH)2D3通过抑制IκB/NF-κB信号通路抑制破骨细胞生成[J]. 第三军医大学学报2021, 43(14): 1339-1345.
12
Martens PJ, Gysemans C, Verstuyf A, et al. Vitamin D’s effect on immune function[J]. Nutrients, 2020, 12(5): E1248.
13
Bishop EL, Ismailova A, Dimeloe S, et al. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory[J]. JBMR Plus, 2021, 5(1): e10405.
14
郑羽旋,魏 迅,张乐文,等. 维生素D与糖尿病关系的研究进展[J]. 中国糖尿病杂志2023, 31(6): 472-475.
15
赵文慧,郭 伟. 维生素D作用与糖尿病关系的研究进展[J]. 生物过程2023, 13(3): 135-141.
16
Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases[J]. Vitam Horm, 2011, 86: 217-237.
17
陈立君. 肺部感染的护理措施[J/CD]. 世界最新医学信息文摘(连续型电子期刊), 2020, 20(7): 111.
18
Bleakley AS, Licciardi PV, Binks MJ. Vitamin D modulation of the innate immune response to paediatric respiratory pathogens associated with acute lower respiratory infections[J]. Nutrients, 2021, 13(1): 276.
19
Ahmad S, Arora S, Khan S, et al. Vitamin D and its therapeutic relevance in pulmonary diseases[J]. J Nutr Biochem, 2021, 90: 108571.
20
Gupta P, Dewan P, Shah D, et al. Vitamin D supplementation for treatment and prevention of pneumonia in under-five children: a randomized double-blind placebo controlled trial[J]. Indian Pediatr, 2016, 53(11): 967-976.
21
Murdaca G, Pioggia G, Negrini S. Vitamin D and COVID-19: An update on evidence and potential therapeutic implications[J]. Clin Exp Allergy, 2020, 18(1): 23.
22
Ma D, Peng L. Vitamin D and pulmonary fibrosis: a review of molecular mechanisms[J]. Int J Clin Exp Pathol, 2019, 12(9): 3171-3178.
23
Bagcchi S. WHO′s Global Tuberculosis Report 2022[J]. Lancet Microbe, 2023, 4(1): e20.
24
Aibana O, Huang C-C, Aboud S, et al. Vitamin D status and risk of incident tuberculosis disease: a nested case-control study, systematic review, and individual-participant data meta-analysis[J]. PLoS Med, 2019, 16(9): e1002907.
25
Soeharto DA, Rifai DA, Marsudidjadja S, et al. Vitamin D as an adjunctive treatment to standard drugs in pulmonary tuberculosis patients: an evidence-based case report[J]. Adv Prev Med, 2019, 2019: 5181847.
26
Papagni R, Pellegrino C, Di Gennaro F, et al. Impact of vitamin D in prophylaxis and treatment in tuberculosis patients[J]. Int J Mol Sci, 2022, 23(7): 3860.
27
Cai L, Wang G, Zhang P, et al. The progress of the prevention and treatment of Vitamin D to tuberculosis[J]. Front Nutr, 2022, 9: 873890.
28
Wang J, Feng M, Ying S, et al. Efficacy and safety of vitamin D supplementation for pulmonary tuberculosis: a systematic review and meta-analysis[J]. Iran J Public Health, 2018, 47(4): 466-472.
29
Jolliffe DA, Ganmaa D, Wejse C, et al. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data[J]. Eur Respir J, 2019, 53(3): 1802003.
30
Mily A, Rekha RS, Kamal SMM, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial[J]. PLoS One, 2015, 10(9): e0138340.
31
Maes K, Serré J, Mathyssen C, et al. Targeting vitamin D deficiency to limit exacerbations in respiratory diseases: utopia or strategy with potential?[J]. Calcif Tissue Int, 2020, 106(1): 76-87.
32
Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide[J]. Eur J Clin Nutr, 2020, 74(11): 1498-1513.
33
Mims JW. Asthma: definitions and pathophysiology[J]. Int Forum Allergy Rhinol, 2015, 5(S1): S2-S6.
34
Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma[J]. Cochrane Database Syst Rev, 2016, 9: CD011511.
35
Cherrie MPC, Sarran C, Osborne NJ. Association between serum 25-hydroxy vitamin D levels and the prevalence of adult-onset asthma[J]. Int J Environ Res Public Health, 2018, 15(6): E1103.
36
Liu M, Wang J, Sun X. A meta-analysis on vitamin D supplementation and asthma treatment[J]. Front Nutr, 2022, 9: 860628.
37
Liu J, Dong Y-Q, Yin J, et al. Meta-analysis of vitamin D and lung function in patients with asthma[J]. Respir Res, 2019, 20(1): 161.
38
Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data[J]. Lancet Respir Med, 2017, 5(11): 881-890.
39
Pfeffer PE. Targeting the exposome: does correcting vitamin D deficiency have potential to treat and prevent asthma?[J]. Expert Rev Clin Immunol, 2018, 14(4): 241-243.
40
Davidson BL, Alansari K. Vitamin D deficiency can impair respiratory health[J]. Respirology, 2018, 23(6): 554-555.
41
Wang M, Liu M, Wang C, et al. Association between vitamin D status and asthma control: a meta-analysis of randomized trials[J]. Respir Med, 2019, 150: 85-94.
42
Chen Z, Peng C, Mei J, et al. Vitamin D can safely reduce asthma exacerbations among corticosteroid-using children and adults with asthma: a systematic review and meta-analysis of randomized controlled trials[J]. Nutr Res, 2021, 92: 49-61.
43
Rafiq R, Thijs W, Prein R, et al. Associations of serum 25(OH)D concentrations with lung function, airway inflammation and common cold in the general population[J]. Nutrients, 2018, 10(1): E35.
44
Pfeffer PE, Hawrylowicz CM. Vitamin D in asthma: mechanisms of action and considerations for clinical trials[J]. Chest, 2018, 153(5): 1229-1239.
45
Hall SC, Agrawal DK. Vitamin D and bronchial asthma: an overview of data from the past 5 years[J]. Clin Ther, 2017, 39(5): 917-929.
46
Cho SW, Kim JH, Choi JH, et al. Preventive and therapeutic effects of vitamin D in a mouse model of allergic asthma[J]. Asian Pac J Allergy Immunol, 2019, 37(3): 130-137.
47
Souto Filho JTD, de Andrade AS, Ribeiro FM, et al. Impact of vitamin D deficiency on increased blood eosinophil counts[J]. Hematol Oncol Stem Cell Ther, 2018, 11(1): 25-29.
48
Szymczak-Pajor I, Kleniewska P, Wieczfinska J, et al. Wide-range effects of 1,25(OH)2D3 on group 4A phospholipases is related to nuclear factor κ-B and phospholipase-A2 activating protein activity in mast cells[J]. Int Arch Allergy Immunol, 2020, 181(1): 56-70.
49
Pfeffer PE, Lu H, Mann EH, et al. Effects of vitamin D on inflammatory and oxidative stress responses of human bronchial epithelial cells exposed to particulate matter[J]. PLoS One, 2018, 13(8): e0200040.
50
Sun D, Luo F, Xing JC, et al. 1,25(OH)2D3 inhibited Th17 cells differentiation via regulating the NF-κB activity and expression of IL-17[J]. Cell Prolif, 2018, 51(5): e12461.
51
Shabana MA, Esawy MM, Ismail NA, et al. Predictive role of IL-17A/IL-10 ratio in persistent asthmatic patients on vitamin D supplement[J]. Immunobiology, 2019, 224(6): 721-727.
52
Ma JG, Wu GJ, Xiao HL, et al. Vitamin D has an effect on airway inflammation and Th17/Treg balance in asthmatic mice[J]. Kaohsiung J Med Sci, 2021, 37(12): 1113-1121.
53
Williamson A, Martineau AR, Sheikh A, et al. Vitamin D for the management of asthma[J]. Cochrane Database Syst Rev, 2023, 2: CD011511.
54
Kumar J, Kumar P, Goyal JP, et al. Vitamin D supplementation in childhood asthma: a systematic review and meta-analysis of randomised controlled trials[J]. ERJ Open Res, 2022, 8(1): 662-2021.
55
慢性阻塞性肺疾病急性加重诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志2017, 37(14): 17.
56
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals[R]. Fontana: GOLD, Inc., 2023.
[1] 张秋子, 胡利梅, 陈雅茹, 左丽, 任卫东. 维生素D水平与亚急性甲状腺炎预后的相关性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 217-219.
[2] 马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[3] 程炜炜, 张青, 张诚实, 冯契靓, 陈荣荣, 赵云峰. 全身免疫炎症指数与慢性阻塞性肺疾病急性加重期病情严重程度相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 580-584.
[4] 杨万荣, 任治坤, 时新颍. 沙丁胺醇雾化吸入脾多肽治疗AECOPD的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 609-612.
[5] 赖乾德, 吕相琴, 蔺洋, 刘媛梅, 赵春艳, 李琦. 肝素结合蛋白对慢性阻塞性肺疾病预后预测分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 613-616.
[6] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[7] 方晓玉, 王婷, 赵珊, 陈锋. HALP指数对AECOPD并发呼吸衰竭患者ICU结局的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 639-641.
[8] 郭少琳, 郭建英, 左秀萍, 高苗. 慢性阻塞性肺疾病康复训练依从性影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 652-654.
[9] 杨坤, 赵景成, 吴永强. 无创呼吸机在慢性阻塞性肺疾病并发呼吸衰竭救治的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 481-483.
[10] 孔令梅, 徐晓媛, 马丽颖. 慢性阻塞性肺疾病认知衰弱危险因素及预后分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 407-410.
[11] 徐艳, 江秀娟, 王超, 江圆满. 股直肌剪切波弹性成像对COPD并发肌少症的诊断意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 454-457.
[12] 黄映兰, 骆丽萍, 郭慧玲, 袁麟标. 慢性阻塞性肺疾病糖皮质激素治疗反应性的影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 469-471.
[13] 宋素莉, 贺英华, 陈丽娟. COPD并发吸入性CAP危险因素及病原菌分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 264-267.
[14] 梁粟, 王建玲, 张晓静. 中药穴位贴敷治疗肺胃热盛型小儿支气管肺炎的临床研究[J]. 中华针灸电子杂志, 2024, 13(02): 65-68.
[15] 徐韫健, 吴柳, 尹小毛. 结核病γ-干扰素释放试验假阴性的影响因素分析[J]. 中华临床实验室管理电子杂志, 2024, 12(02): 75-79.
阅读次数
全文


摘要